Zolpidem ( DrugBank: Zolpidem )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
5	進行性核上性麻痺	1
6	パーキンソン病	3
46	悪性関節リウマチ	1

5. 進行性核上性麻痺

---

臨床試験数 : 95 /  薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04014387 (ClinicalTrials.gov)	June 2, 2019	11/4/2019	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment	Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule	University of California, San Francisco	US Department of Veterans Affairs	Recruiting	18 Years	N/A	All	60	Phase 4	United States

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03621046 (ClinicalTrials.gov)	August 20, 2018	6/6/2018	Use of Low-dose Zolpidem in Parkinson's Disease	A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's	Parkinson Disease	Drug: Zolpidem;Other: Placebo	Aston University	University Hospital Birmingham NHS Foundation Trust	Completed	40 Years	80 Years	All	28	Phase 2	United Kingdom
2	EUCTR2017-004297-34-GB (EUCTR)	31/03/2018	22/06/2018	Use of low-dose zolpidem in Parkinson's.	A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Stilnoct Product Name: Stilnoct Product Code: 207-3120 INN or Proposed INN: Zolpidem Tartrate	Aston University	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	United Kingdom
3	NCT01351168 (ClinicalTrials.gov)	December 2011	9/5/2011	Use of Zolpidem in Parkinson's Disease	A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease	Parkinson's Disease	Drug: Levodopa;Drug: Zolpidem first dose;Drug: Zolpidem second dose;Drug: sugar pill	Rush University Medical Center	NULL	Withdrawn	30 Years	75 Years	Both	0	Phase 2	United States

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000039116	2020/01/15	15/01/2020	Effects of Sleep Management on Postoperative Pain in patients after total knee arthroplasty. A randomized controlled study.	Effects of zolpidem tartrate on Postoperative Pain in patients after total knee arthroplasty. A randomized controlled study. - SMAPP	Osteoarthritis, Rheumatoid arthritis	Administration of zolpidem tartrate of 5mg for 7 days after surgery No administration of zolpidem tartrate	Mito medical center, Mito Kyodo General Hospital, University of Tsukuba	NULL	Pending	20years-old	Not applicable	Male and Female	84	Not selected	Japan

先頭へ